Newsfile Corp
18 Jun 2026, 19:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
GeneDx lowered its full-year revenue guidance to $475-$490 million, down from $540-$550 million. — A significant reduction in top-line guidance indicates deteriorating growth prospects and weakens valuation.
-0.70GeneDx reported a $31.2 million impairment loss related to its acquisition of Fabric Genomics. — Impairment charges signal that a previous strategic acquisition failed to deliver the expected value, suggesting poor capital allocation.
-0.60GeneDx is facing a securities class action lawsuit alleging the company failed to disclose material information during the class period. — Legal action for securities fraud creates regulatory risk and potential future financial liabilities.
-0.50Continue reading
6 related stories
Top 1 mover · tap to explore
The company's adjusted gross margin dropped from 74% to 69% in the first quarter of fiscal year 2026. — Margin compression suggests increasing costs or declining pricing power, negatively impacting profitability.
-0.40GeneDx missed revenue estimates for both its exome and genome product lines. — Missing targets across core product lines suggests a broad systemic decline in demand or competitive pressure.
-0.30Which stocks this story touches
The company is facing a securities class action lawsuit following a 49.2% stock price drop, missed revenue estimates, and a $31.2 million impairment loss.
The company is mentioned in the context of a class action lawsuit application deadline.
The company is mentioned in the context of a class action lawsuit application deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
